Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-923-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$900,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) released its earnings results on Thursday, August, 8th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.07. The company earned $0.01 million during the quarter. View Selecta Biosciences' Earnings History.
When is Selecta Biosciences' next earnings date?
What price target have analysts set for SELB?
6 analysts have issued 12-month price targets for Selecta Biosciences' shares. Their predictions range from $4.00 to $13.00. On average, they expect Selecta Biosciences' share price to reach $8.20 in the next twelve months. This suggests a possible upside of 477.5% from the stock's current price. View Analyst Price Targets for Selecta Biosciences.
What is the consensus analysts' recommendation for Selecta Biosciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (10/10/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after SELB reported its 2Q19 financial and business update. We are encouraged by the company’s announced partnership with AskBio to develop gene therapies leveraging SELB’s ImmTOR platform, which may allow for re- dosing, but could also confer benefits on first dosing as well. While the announcement is a nice positive, no upfront cash or non-dilutive financing was secured through the deal, something we would have liked to see given the company’s capital overhang, which is a growing concern. While the interim results of the COMPARE study, which are expected in 4Q19, remain the key event for the stock, the study’s design using Krystexxa as a monotherapy may not fully de-risk the program commercially in the eyes of investors though, we do think it will further de-risk SEL-212 from a safety/efficacy perspective and inform the Phase 3 study design." (8/9/2019)
- 3. Mizuho analysts commented, "We believe these readouts will be key drivers for SELB shares in late 2019/early 2020." (5/10/2019)
Has Selecta Biosciences been receiving favorable news coverage?
Headlines about SELB stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Selecta Biosciences earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Selecta Biosciences.
Are investors shorting Selecta Biosciences?
Selecta Biosciences saw a drop in short interest in September. As of September 30th, there was short interest totalling 728,100 shares, a drop of 5.0% from the August 30th total of 766,800 shares. Based on an average daily trading volume, of 140,600 shares, the short-interest ratio is currently 5.2 days. Currently, 2.4% of the company's shares are sold short. View Selecta Biosciences' Current Options Chain.
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include resTORbio (TORC), ProQR Therapeutics (PRQR), Seres Therapeutics (MCRB), MannKind (MNKD), Provention Bio (PRVB), Xeris Pharmaceuticals (XERS), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT), Applied Therapeutics (APLT), Xenon Pharmaceuticals (XENE), Albireo Pharma (ALBO), Galectin Therapeutics (GALT), Stealth BioTherapeutics (MITO), Mallinckrodt (MNK) and Aeglea Bio Therapeutics (AGLE).
What other stocks do shareholders of Selecta Biosciences own?
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 50)
- Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 51)
- Dr. John H. Leaman, Exec. Officer (Age 46)
- Dr. Werner Cautreels, Advisor (Age 67)
- Dr. Carsten Brunn, CEO, Pres & Director (Age 48)
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $1.42.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $63.60 million and generates $900,000.00 in revenue each year. The company earns $-65,340,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.View Additional Information About Selecta Biosciences.
What is Selecta Biosciences' official website?
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
